JP2003055231A - Enteral nutrient - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide an enteral nutrient of an oligosaccharide having both of selective proliferation action of bifidobacterium and intestinal function- regulating action of dietary fiber. SOLUTION: This enteral nutrient comprises a mixture of xylooligosaccharides having >=7 and <=20 average polymerization degree. The mixture of xylooligosaccharides is preferably a mixture having <=10 wt.% total content of xylose, xylobiose, xylotriose, xylotetraose and xylopentaose.

Description

Detailed Description of the Invention

[0001]

TECHNICAL FIELD The present invention relates to an enteral nutritional agent which is orally ingested as a food or medicine and is absorbed from the intestine.

[0002]

2. Description of the Related Art Due to the growing interest in public health,
Attempts to maintain good health through the foods eaten daily have received much attention. Especially sugars such as dietary fiber and oligosaccharides,
These decomposition products are also fields that have been very researched in recent years because of their physiological activity exerted in digestive organs. Dietary fiber has historically been regarded as important as a food factor related to basic metabolism of the living body such as carbohydrate metabolism and lipid metabolism. Among functional foods, there are many that claim the action of this dietary fiber. In addition, the aging of the population is progressing, and patients who are bedridden due to illness and those who are administered many drugs during medical treatment often have a burden on the digestive system, and for these people, diet Dietary fiber and oligosaccharides are very important food factors.

The main effect of dietary fiber is to increase fecal weight,
The effects on the digestive organs, the metabolism of nutrients and the like can be mentioned. Among these physiological activities, many studies have been conducted in the fields related to protein metabolism, lipid metabolism, and carbohydrate metabolism. (Southgate, DAT and Durnin, JV
GA: Calorie conversion factors; an experimental
reassesment of the factors used in the calculatio
n.energy value of human diets. Br.J.Nutr. , 24,517
535 (1970)) In recent years, research on the physiological action of dietary fiber on bacterial groups present in the intestine has also attracted attention.

The involvement of dietary fiber in carbohydrate and lipid metabolism has been well studied. In particular, when dietary fiber is ingested at the same time as sugar, absorption of low molecular weight sugar is suppressed, and the amount of insulin in blood is also suppressed. It is also known that ingestion of dietary fiber increases excretion of proteins and lipids in feces, and decreases apparent nutrient absorption capacity. Inhibition of blood sugar elevation and serum cholesterol reduction by dietary fiber intake (Jenkins, DJA, Wolever, TMS, Leed
s, AR, Gassull, MA, Haisman, P., Dilawari, J., Goff, D.
V., Metz, GLand Alberi, KGM: Dietary fibers, fiber
analogues and glucose tolerance; importance viscos
Brit.Med.J. , 1 , 1392 to 1394) and serum cholesterol lowering effects are reported to be useful in the prevention of diseases.

In recent years, there have been cases where IgA (immunoglobulin A) in small intestinal mucosal cells is attempted for the purpose of measuring the health of the small intestine as an organ. For some reason, the small intestine falls into an oligotrophic state or bacterial infection. It has been found that IgA per cell mucosal mass is reduced in patients with necrosis caused by lactobacillus, while excessive IgA production may cause allergies, and proper control of IgA at the intestine is necessary. It is important for the internal environment.There have been some attempts to control IgA by the components contained in the diet, and it seems to be considerably effective in the experimental system using vitamin A, for example. , There seems to be almost no research attempting to elucidate the relationship between dietary fiber and IgA in small intestinal mucosal cells.

Ingestion of dietary fiber increases the volume and weight of feces. To the digested substances in the digestive organs, unnecessary chemical substances are released from the body together with bile acids. Among unnecessary chemical substances, there are carcinogenic substances and hormones that control the metabolism of the living body, but these are usually excreted together with feces. An increase in the weight and volume of stool contributes to the dilution of carcinogens. Therefore, the chance that the surface cells of the digestive organs come into contact with these carcinogenic substances is reduced, and as a result, the incidence of digestive system cancer is significantly reduced.

[0007] However, it has been known that dietary fiber has many opportunities to come into contact with the surface cells of the small intestine and the large intestine, and therefore has many physical and nonspecific effects on these cells. (Ca
ssidy, MM, Lightfood, FG, Grau, LE et al .: Effect o
f chronic intake of dietary fibers on the ultrasut
ractual topography of rat jejunum and colon: asca
nning electron microscopy study. Am.J.Cli.Nutr. , 11
2.6 (1982)) Especially, dietary fiber exfoliates cell groups on the surface of organs,
Drops out and reduces absorption of nutrients in food. For this reason, people in developing countries, which are chronically deficient in nutrients, should refrain from excessive intake of dietary fiber, but in advanced countries such as Japan, they are close to overeating and satiety, and dietary fiber is rather aggressive. Should be ingested to avoid excessive absorption of lipids and sugars. On the other hand, in the digestive system, there is a phenomenon that the health level of cell groups on the surface layer decreases even when a diet containing no dietary fiber is continued, and it is known that a diet containing no dietary fiber greatly impairs health. Has been. In other words, it is suggested that the proper intake of dietary fiber is determined by the amount of nutrients in the diet and the health condition of the ingested human.

[0008] As described above, dietary fiber having a very high degree of polymerization has a merit associated with ingestion, but it also damages the surface cells of the intestinal tract, so in various cases, the mucosal cells of the intestinal tract are weakened. It is necessary to be careful when using it.

[0009] On the other hand, oligosaccharides having a lower degree of polymerization of sugar chains than dietary fiber act in the large intestine after ingestion to selectively grow the bifidobacterium, which is a useful intestinal bacterium, so that it is an active ingredient of functional foods. Has received a great deal of attention. At present, many products that are said to have selective growth properties for Bifidobacterium are on the market. Generally, oligosaccharides are superior to dietary fiber in improving the intestinal bacterial flora. This is because oligosaccharides have a smaller molecular weight than dietary fiber, which is a polymer, and enterobacteria can be easily taken up into cells and utilized.

It is said that, when xylooligosaccharides are used, the selective growth of bifidobacteria exerts a sufficient effect on adult males by ingesting 0.7 to 1.0 g / day. The number of Escherichia coli and Clostridium bacteria in the intestine decreases with the relative increase of Bifidobacterium. As a result, β-glucuronidase derived from Escherichia coli and Clostridium in the large intestine contents is known to decrease. β-Glucuronidase is involved in the enterohepatic circulation of bile acids and promotes reabsorption from the intestinal tract of carcinogenic compounds excreted by glucuronidation. However, in general, oligosaccharides do not have the characteristic properties of dietary fiber such as improvement of lipid metabolism and blood properties accompanying it. In the field of oligosaccharides and dietary fiber, it is desired to develop a substance having both the properties of oligosaccharide and dietary fiber that can control the intestinal action associated with the selective growth of Bifidobacterium and control the metabolism of lipids and carbohydrates. It was rare.

[0011]

To solve the above problems, the present invention includes the following inventions. (1) An enteral nutritional product containing a xylooligosaccharide composition, wherein the xylose polymer has an average degree of polymerization of 5 or more and 20 or less. (2) The xylooligosaccharide which is the xylooligosaccharide composition according to (1) above, and has a total content ratio of xylose, xylobiose, xylotriose, xylotetraose and xylopentaose contained in the mixture of 10% by weight or less. An enteral nutritional product containing a sugar mixture. (3) An enteral nutritional product containing 0.1% by weight or more of the xylooligosaccharide according to (1) above.

[0012] As a result of continuing intensive studies, the present inventors have invented a long-chain xylooligosaccharide capable of reaching the large intestine without damaging the small intestinal mucosa and selectively growing bifidobacteria there. Moreover, this long-chain xylooligosaccharide also has the characteristics of dietary fiber, and not only can it control lipid metabolism such as cholesterol and phospholipids in blood, but can also control the amount of IgA in small intestinal mucosal cells by ingesting an appropriate amount. It was found to be sugar and the present invention was completed. This novel xylooligosaccharide can be used as an enteral nutritional agent by oral administration.

[0013]

BEST MODE FOR CARRYING OUT THE INVENTION The present invention will be specifically described below. The long-chain xylooligosaccharide, which is the main ingredient of the enteral nutrition of the present invention,
It is a mixed composition of xylooligosaccharides having a relatively high degree of polymerization, and has an average degree of polymerization of 5 or more and 20 or less. The degree of polymerization 5 means a pentamer of xylose, and the degree of polymerization 20 means a 20mer of xylose. Among long-chain oligosaccharides having an average degree of polymerization of 5 or more, those having an average degree of polymerization of 10 to 20 are more preferable as the enteral nutrient.
The thing of 11-18 is more preferable. The most preferable average degree of polymerization is 12 to 15. The long-chain xylooligosaccharide may be any organic substance whose main component is lignocellulose containing xylan as a starting material, but preferably hardwood kraft pulp (hereinafter referred to as LOKP) or softwood kraft pulp (hereinafter referred to as NOKP) is treated with xylanase. It can be obtained relatively easily by purifying from a xylooligosaccharide solution having an average degree of polymerization of about a pentamer, which is purified from the treatment liquid. This is because even if the average degree of polymerization is said to be around the pentamer, it contains about 1 to 3% of long-chain xylooligosaccharides.

Since a relatively large amount of re-adsorbed xylan chains are present on the surface of LOKP or NOKP, a xylooligosaccharide solution can be obtained relatively easily. Also, a very important point is that the re-adsorbed xylan present on the surface of LOKP and NOKP forms a complex with lignin and is re-adsorbed, so that xylanase acts on the xylan sugar chain during hydrolysis by xylanase. Has few hydrolysis sites. Therefore, a relatively large xylooligosaccharide chain can be obtained. On the other hand, when rice straw or corn cob is used as a lignocellulosic material,
The length of the obtained sugar chain is quite short, and normally disaccharide or trisaccharide is obtained as the final product. For the above reasons, it is very difficult to produce a xylooligosaccharide having a degree of polymerization of 10-mer or more with a normal lignocellulosic material.

A method for treating kraft pulp with xylanase and purifying xylo-oligosaccharide from the treated liquid is disclosed in JP-A-2000-200.
It is described in detail in Japanese Patent Publication No. 00-333692. XN
No. 10 can be purified from the oligosaccharide solution obtained by treating the xylooligosaccharide-lignin complex in this xylanase-treated solution with a dilute acid to remove lignin, and then desalting and decolorizing. The xylooligosaccharide solution obtained by the method described in JP-A-2000-333692 described above has an average degree of polymerization of the xylooligosaccharide in the solution of around the pentamer. However, in this oligosaccharide solution, about 1 chain length or more is 10 or more.
It was found by the measurement of the present inventors that the content is about 3% to 3%. In fact, when this solution is concentrated to about 10%, xylooligosaccharides having a long chain length become insoluble and precipitate. When the supernatant of this precipitate was removed, a xylooligosaccharide having an average degree of polymerization of around 12-mer was obtained, which was named XN10. XN10 has a sugar composition of almost 100% xylose and does not contain glucose, arabinose, or 4-O-methylglucuronic acid.

This XN10 is different from existing xylooligosaccharides,
It is a novel oligosaccharide that has both the properties of dietary fiber and the properties of oligosaccharides. 4 using XN10 and xylobiose
When an in VIVO test was performed using week-old SD rats, the total cholesterol and phospholipid contents in the blood of the xylobiose-administered group were almost the same as those of the control group, but the total amount of XN10-administered group was the same. The contents of cholesterol and phospholipid were significantly decreased. Therefore, XN10 is expected to be an oligosaccharide that can be expected to improve hyperlipidemia by ingestion.

Xylooligosaccharides are Bifidobacterium animalis, which is a rat intestinal bacterium regardless of sugar chain length.
It is possible to increase the abundance ratio of C. in cecal contents by about 100 times. On the other hand, E. coli which is also a rat intestinal bacterium .
Escherichia coli can be significantly reduced compared to before administration of oligosaccharide. Β-Glucuronidase activity in cecal contents tended to decrease in the oligosaccharide-administered group, with xylobiose and XN
Compared with 10, XN10 has about twice as high inhibitory activity,
It is likely to reduce the incidence of colorectal cancer.

The pH of the contents of the cecum decreases with the increase in the number of useful enteric bacteria, Bifidobacteria and lactic acid bacteria, due to the organic acids produced by these bacteria. It is known that the organic acid produced at this time is absorbed from the intestinal tract and serves as an energy source for these mucosal cells. Therefore, the intestinal mucosal cells of the group in which long-chain xylooligosaccharides were administered and the amount of bifidobacteria in rat cecal contents was increased because energy can be obtained from the organic acids produced by bifidobacteria and lactic acid bacteria, actively divide, It is possible to grow.

In addition, XN10 was ingested in the intestinal mucosal cells by ingestion.
The content of IgA can be significantly increased. In the above experimental system, XN10 can increase the amount of IgA in small intestinal mucosal cells with a small amount of administration, and therefore contributes to the revival of small intestinal mucosal cells exhausted by anticancer agents, other drugs, infections and the like. Few members of dietary fiber and oligosaccharides have the ability to specifically increase IgA. Therefore, effective intake of XN10 can control the flora of intestinal bacteria and control the production of IgA, which can prevent damage from O-157 and other infectious diseases. Is.

[0020]

EXAMPLES The contents of the present invention will be described below with reference to examples, but it goes without saying that the contents of the present invention are not limited to the scope of the examples.

<Measurement method> (1) Quantification of total sugar amount The total sugar amount was prepared by using a calibration curve using D-xylose (manufactured by Wako Pure Chemical Industries, Ltd .: product number 244-00302), and using the phenol-sulfuric acid method (“reducing sugar”). Quantitative method ”published by the Academic Publishing Center). (2) Quantification of reducing sugar amount The reducing sugar amount is shown by a calibration curve with D-xylose (manufactured by Wako Pure Chemical Industries:
Part No. 244-00302), and quantified by the Somodi-Nelson method ("Quantitative method for reducing sugars" published by the Society Press Center). (3) Method of determining average degree of polymerization Sample sugar solution is kept at 50 ° C for 15 min at 15000 rpm
Centrifuge to remove insoluble matter. The average degree of polymerization was determined by dividing the total sugar amount in the supernatant by the reducing sugar amount (both converted to xylose). (4) Analysis by ion chromatography Ion chromatography (Dionex) was used for analysis of xylooligosaccharides. Carbo Pac PA-10 (Dionex) as a column suitable for sugar analysis
Was used.

<Preparation of long-chain xylooligosaccharide> As a starting material, a neutral xylooligosaccharide having an average degree of polymerization of 5.2 adjusted by the method described in JP-A-2000-333692 was used as a starting material. 70 g of the starting material is dispersed in 1000 ml of ultrapure water and stirred well. The starting material does not completely dissolve in 1000 ml of pure water, and an apparently cloudy liquid is provided.
When this cloudy liquid is left to stand at room temperature for 24 hours, only insoluble long-chain oligosaccharides are precipitated. Therefore, when the supernatant is gently removed by a perista pump, only white long-chain xylooligosaccharides are recovered. The white precipitate had a sugar content of 497 mg. This white precipitate was designated as XN10, the white precipitate was 60 ° C, 50 ml.
When it is suspended in ultrapure water, it completely dissolves and becomes a colorless transparent liquid. Dry powder XN10 could be obtained by spray drying this transparent liquid. The weight of XN10 at this time was
It was 455 mg. The results of ion chromatography analysis of XN10 are shown in FIG. The vertical axis represents the redox potential (nC), and the horizontal axis represents the elution time. As shown in the figure, the elution time is 17
Long-chain xylooligosaccharides are eluted before and after the minute.

<Polymerization degree of XN10> The obtained XN10 powder was dissolved in ultrapure water to prepare a 1% aqueous solution. The average degree of polymerization was determined by measuring the total sugar amount by the phenol-sulfuric acid method, and then measuring the reducing sugar amount in a 1% aqueous solution by the Somogene Nelson method. A calibration curve was prepared using D-xylose in all measurements. The average degree of polymerization was determined by dividing the total sugar amount per 1 ml by the reducing sugar amount per 1 ml. As a result, XN10 produced by the above method
The average degree of polymerization of was 2.3. This is a long-chain xylooligosaccharide having a higher degree of polymerization than the starting material having an average degree of polymerization of 5.2.

<Physiological action of XN10> Using the oligosaccharides of XN10 prepared this time, experiments were conducted on the physiological activity of these oligosaccharides on the digestive organs of rats. The rats used were SD male rats, 6 weeks old. The addition rate of oligosaccharides to the diet was uniformly 2%, and in the group in which no oligosaccharide was added (control group), α-corn starch was used in place of the oligosaccharide to adjust the weight to prepare a diet. In addition, 5 rats were used in each of the 4 groups including the control group. After preliminarily breeding for 3 days in the facility, food was administered for 4 consecutive weeks, and all rats were dissected 4 weeks later to obtain various data. Table 1 shows the composition of each ingredient in the diet.
Shown in.

[0025]

[Table 1]

[Table 1]

<Intestinal regulation of XN10> After dissection, the intestinal bacterial flora in each group was assayed. Generally, the ratio between the number of good bacteria and the number of bad bacteria in the intestine is a standard for knowing the intestinal health. E. coli was measured as a representative of bacteria that have a bad effect on the living body in the intestine. On the other hand, as a representative of bacteria that bring about good effects in the intestine
Bifidobacterium animalis was measured. As a result, irrespective of oligosaccharide chain length, Bifido
The number of bacterium animalis cells was increased. On the other hand, the number of Escherichia coli per 1 g of cecal contents was also decreased. For comparison, in the above experimental system, a similar experiment was conducted using xylobiose (hereinafter referred to as XB, manufactured by Wako Pure Chemical Industries, Ltd .: product number 242-00641) instead of XN10, and the physiological activity of oligosaccharides in the digestive organs was assayed. The above results are shown in Figure 2.
Shown in. The vertical axis is the logarithm of the number of bacteria per 1 g of cecal contents. As is clear from the figure, although XN10 is a long-chain xylooligosaccharide, it was found to have exactly the same effect as xylobiose, which has already been clarified for selective growth of bifidobacteria.

<Inhibitory action of β-glucuronidase in cecal contents> When β-glucuronidase activity in cecal contents was measured in the above experimental system, the activity was significantly decreased in the oligosaccharide-added group as compared with the control group. ,In particular
The XN10-added plots were significantly lower than the control and XB-added plots. In particular, the β-glucuronidase activity was reduced by 58% in the XN10-added group compared to the control. In addition, when comparing the XB administration group and the XN10 administration group, the XN10 administration group
The β-glucuronidase activity was 43% lower than that of the XB-administered group. β-glucuronidase is an enzyme that has been pointed out to have the potential to induce colon cancer, and β-glucuronidase is a β-glucuronidase in cecal contents.
The lower the glucuronidase activity, the better. Most of the β-glucuronidase activity in the digestive organ contents is derived from enterobacteria. It is considered that the addition of oligosaccharides to the diet affected the intestinal bacteria and reduced the expression level of enzyme activity. This is shown in FIG.

<Effect of XN10 on blood properties: hyperlipidemia improving action> Blood of each rat was taken at the time of dissection and plasma was analyzed by an analyzer to analyze various plasma components. The analysis was carried out by using an automatic blood analyzer (CL-8000) manufactured by Shimadzu Corporation, and each component was used by a measurement kit manufactured by Cellotech Co. as a result
TG (triglyceride), Tcho (total cholesterol), Fcho (free fatty acid), PL (phospholipid), β-Lip
It was found that (β-lipoprotein) and the like were significantly decreased as compared with the control group, and the oligosaccharide-added diet had the potential of improving hyperlipidemia. On the other hand, other blood property guidelines such as GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transaminase), ALP (alkaline phosphatase), LAP (leucine aminopeptidase), and Glu (blood sugar) are control groups and oligos. No significant difference was observed with the sugar-added group. Of the above, the results of triglyceride, β-lipoprotein, and total cholesterol are shown in FIGS. 4 to 6.

<XN10's ability to promote IgA production in small intestinal mucosal cells>
Next, the characteristics of the small intestine mucosal cells at the time of dissection were examined. The small intestine was divided into four equal parts after dissection, and they were divided into 1/4 segment, 2/4 segment, 3/4 segment, and 4/4 segment. The 2/4 segment, 4/4 segment small intestine was subjected to analysis. The small intestine of both segments is inverted inside and outside, and the mucosal cells are scraped off with a slide glass etc. and collected.
Was used for analysis.

The measurement of IgA in mucosal cells was performed as follows. 9 times the amount of small intestinal mucosal cells BSA dilient / blockin
Homogenate with g solution (15-fold dilution). This is 10
After centrifugation at 000 rpm for 10 minutes, the supernatant was used as a sample. IgA of this sample was measured according to the following procedures (1) to (8). (1) Diluted 2000 times in 96-well microplate
Primary antibody (Rabbit anti rat IgA, BETHYL LABORATORIES, I
NC. (Product number A110-104, product name ANTI RAT IGA (RABBIT)) 50
μl was added and left overnight. (2) After washing twice with PBS tween 20, the standard (R
at IgA, Zymed Lab. Inc. (Manufacturer code ZYM-02-9488))
And 50 μl of the sample were added and left at 37 ° C. for 2 hours. (3) After washing 3 times with PBS tween20, add 32000 to each well.
Double-diluted secondary antibody (mouse anti rat IgA, Dainippon Pharmaceutical)
(Manufacturer code DNS-MCA191)) (50 μl) and add 37 ℃
I left it for 1 hour. (4) After washing 3 times with PBS tween20, add 100 times diluted (diluted with 0.1M PBS) Horse serum (in ABC Kit) to each well.
50 μl was added and left at 37 ° C. for 30 minutes. (5) After washing 3 times with PBS tween20, add 50 μl of biotinylated tertiary antibody (horseanti mouse IgG, (ABC Kit Funakoshi Co., Ltd. (manufacturer code FNK41-0761-02)) to each well at 37 ° C. (6) After washing 3 times with PBS tween20, 50 μl of ABC reagent was added to each well and left for 1 hour at 37 ° C. (7) After washing 3 times with PBS tween20, each well was washed. ABTs Peroxidase Su as a substrate for peroxidase in wells
50 μl of bstrate / HO reagent (Funakoshi Co., Ltd.) was added and reacted. (8) After that, microplate reader (Bio-Rad, MODEL
550), 405nm (mesurement), 550nm (referenc
The absorbance of e) was measured. A standard curve was prepared from the results of this absorbance and the concentration of each sample was determined.

As a result of the measurement by the above method, the amount of IgA in the small intestinal mucosa of each group was significantly different in the 4/4 node. XN1
In the 0-administered group, the per-mucosal weight increased 4.4 times as compared with the control group. The result is shown in FIG. 7. The vertical axis represents the amount of IgA per mucosal weight. It is speculated that xylo-oligosaccharides including XN10 may increase the intestinal tract immunity by increasing the amount of IgA in mucosal cells.

[0032]

INDUSTRIAL APPLICABILITY According to the present invention, enteral nutrition having an unprecedented new function was obtained. This novel enteral nutrient contains a novel long chain xylooligosaccharide composition. Long-chain xylooligosaccharides are resistant to acid hydrolysis and are not degraded by gastric acid. In addition, it is a unique oligosaccharide having an antihyperlipidemic action which is a dietary fiber-like action and an intestinal regulating action derived from selective growth of bifidobacteria which is a main action of oligosaccharides. Xylooligosaccharide itself is an extremely safe substance for the human body who has experienced eating, and can be sufficiently used for foods, pharmaceuticals and the like. In particular, one of the novel physiological activities of long-chain xylooligosaccharides is the ability to increase IgA production in the small intestinal mucosa. When long-chain xylooligosaccharides are used in enteral nutritional products that are administered to humans with weakened intestinal immunity, IgA production is increased, resistance to infectious diseases is increased, and the health of users is improved. It is considered that it will make a large contribution.

[Brief description of drawings]

FIG. 1 shows the results of ion chromatography analysis of long-chain xylooligosaccharides used in the examples.

FIG. 2 is a view showing the growth property of Bifidobacterium.

FIG. 3: Results of β-glucuronidase activity measurement of cecal contents.

FIG. 4 shows the measurement results of the amount of triglyceride in plasma.

FIG. 5 shows the measurement results of the amount of β-lipoprotein in plasma.

FIG. 6 shows the measurement results of total cholesterol in plasma.

FIG. 7 shows the results of measuring the amount of IgA in the small intestine.

   ─────────────────────────────────────────────────── ─── Continued front page    (72) Inventor Kaya Izumi             Made by Oji 1-10-6 Shinonome, Koto-ku, Tokyo             Paper Co., Ltd. Shinonome Research Center (72) Inventor Seiji Nakagame             Made by Oji 1-10-6 Shinonome, Koto-ku, Tokyo             Paper Co., Ltd. Shinonome Research Center (72) Inventor Yasuhiro Kido             13-1 Yoshidahonmachi, Sakyo Ward, Kyoto City, Kyoto Prefecture (72) Inventor Yukihiro Nakabo             1-40 Matsudaira Chikuzen, Momoyama-cho, Fushimi-ku, Kyoto-shi, Kyoto Prefecture               L City Momoyama Goryo 312 F-term (reference) 4B018 MD31 ME11                 4C057 BB04                 4C086 AA01 AA02 EA01 MA01 MA03                       MA04 MA52 NA14 ZC21 ZC33                 4C090 BA04 BB10 BB52 BC01 DA23

Claims (3)

[Claims] 1. An enteral nutritional product containing a xylooligosaccharide composition, wherein the xylose polymer has an average degree of polymerization of 5 or more and 20 or less. 2. The xylooligosaccharide composition according to claim 1, wherein the total content of xylose, xylobiose, xylotriose, xylotetraose, and xylopentaose contained in the mixture is 10% by weight or less. An enteral nutritional product containing a xylooligosaccharide mixture. 3. The xylo-oligosaccharide according to claim 1,
An enteral nutritional supplement containing 1% by weight or more.